Cardiovascular disease develops in a slow and subclinical manner over decades, only to manifest suddenly and unexpectedly. Prevention is crucial, both before and after clinical appearance, Report: Dr Eduardo de la Sota
Cardiomyopathy is a disease with many faces, a 'chameleon', according to Professor Jeanette Schulz-Menger. MRI benefits and potential should be communicated better and to a wider clinical audience. Report: Axel Viola
In the year of its 40th anniversary, Schiller proudly presents an algorithm which immediately and accurately localises coronary occlusions and provides early detection of STEMI. This algorithm is now integrated in the sophisticated touch ECG devices, the Cardovit MS line.
CardioSecur, a personalised mobile 12-lead ECG system with four electrodes for iPhone and iPad, enables patients to monitor their symptoms and transmit the data to their physicians in less than a minute.
By recognition and early intervention against the most significant risk factors, many heart diseases can be prevented.
The ‘Fire of Life’ developed by Schiller is an intuitive visual presentation of frequency-domain heart rate variability (HRV) that makes the assessment of 24-hour results fast and simple.
In uncomplicated stable angina cases no evidence suggests that angioplasty reduces heart attacks or death risks, Mark Nicholls reports
The heart is a structure in three dimensions and today we see it in three dimensions,’ Jose Luis Zamorano Gomez MD declared with satisfaction.
Researchers at Johns Hopkins Bayview Medical Center used two relatively simple tactics to significantly reduce the number of unnecessary blood tests to assess symptoms of heart attack and chest pain and to achieve a large decrease in patient charges.
It was the quiet before the storm. At the end of March, during the American College of Cardiology (ACC) meeting in Washington, the future of renal denervation was about to be decided with the presentation of the Medtronic-funded Simplicity HTN-3 clinical trial.
Synchronised Cardiac Assist i-cor, which the company reports to be the first system that links mechanical circulatory support to the heartbeat.
Biotronik, a leading manufacturer of cardiovascular medical technology, announced CE approval for its new Eluna pacemaker series. The new generation of pacemakers includes single and dual-chamber as well as cardiac resynchronization (CRT-P) devices.
It is the quiet before the storm. At the end of March, the future of renal denevation will be decided with the presentation of the Simplicity HTN-3 clinical trial at the American College of Cardiology meeting in Washington.
Fully implantable mechanical hearts bring hope to 121,000 heart failure patients who will never receive a heart transplant
Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, announced that it has received CE Mark in Europe and is initiating the launch of its most advanced transcatheter aortic valve, the Edwards SAPIEN 3 valve.
Despite the availability of cardioversion, ablation and medications to treat AF, outcomes are often poor because it is unclear which patients will benefit most. A new classification of atrial fibrillation (AF) by electrocardiogram (ECG) is set to be developed by European experts to aid personalised management of this devastating condition.
The Plaque-CharM project funded by the German Federal Ministry of Education and Research is to develop novel sensor technology that can characterise arterial tissue in the smallest space – the tip of a catheter.
Since minimally invasive surgery (MIS) entered cardiac surgery in the mid-1990s it became unthinkable not to use this medical specialty. However, MIS procedures do not always result in the best outcome for patients.
Prevention Suite’s four combined imaging technologies enables practical pre-clinical assessment of cardiovascular disease risk .
Ahead of regulatory approval that is expected before the end of the year, Trinity Biotech chose Medica to present the novel point-of-care (POC) analyzer Meritas with the Troponin I (TnI) that are expected to disrupt a €700 million market.
In 1839 Richard Thoma was the first to observe that arteries respond to flow: he identified a fundamental relationship between blood flow and arterial calibre.
The C-Pulse, manufactured by Australian-American company Sunshine Heart, Inc. is neither a pulsatile artificial heart nor one of the well-known non-pulsatile left heart support systems
About 500,000 people in France people suffer heart failure (HF). In Europe the figure is six million and the same in the USA.
‘Cardiology is one of the most innovative medical disciplines. Many modern technologies, such as catheterisations or imaging procedures, were triggered by cardiology,’ declared Professor Dr Gerald Maurer MD.
A new procedure may help people with persistent hypertension. By burning or ablating the nerves in the renal arteries, blood pressure levels can be reduced significantly.
